In the current study, we hypothesized that COX-2 expression would be associated with poor breast cancer survival, and that the COX-2 effect on survival would be modified by the tumor ER and human epidermal growth factor receptor 2 (HER2) status and/or Akt pathway activation. The gene discussed is ESR1; the disease is breast carcinoma.